PISCATAWAY, N.J. – Camber Pharmaceuticals is pleased to announce the addition of dabigatran etexilate capsules to its current portfolio.

 Dabigatran etexilate capsules are a direct thrombin inhibitor, indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.

 Dabigatran etexilate capsules from Camber are available in 75 and 150 mg strengths in 60 count bottles.